Allergan Aesthetics has revamped its loyalty program, restructuring incentives for aesthetic practitioners and practices. The move reflects intensifying competition from biosimilar Botox (ABP-450) and generic filler alternatives, as well as the need to lock in high-volume injectors through improved rebate and purchase terms.
Business & M&A
Allergan Aesthetics Overhauls Loyalty Program
Refreshed Allergan Partner Privileges aims to strengthen injector retention amid biosimilar competition.
1-YEAR MOVE
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |
Allergan is tightening loyalty terms as biosimilar Botox gains traction.
Program details remain limited in available reports, but loyalty overhauls typically involve tiered rebate structures, volume commitments, and exclusive pricing. For practice owners, the timing matters: biosimilar adoption is accelerating, and manufacturers are competing aggressively on economics. Practices should audit current rebate yields against the refreshed Allergan terms and compare to Galderma (Dysport, Restylane) and Evolus (Jeuveau) alternatives before committing to higher volume thresholds.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.